Atyr PHARMA (NASDAQ:ATYR) Research Coverage Started at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Atyr PHARMA (NASDAQ:ATYR) in a research note released on Thursday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $9.00 price target on the stock.

Other analysts have also recently issued reports about the company. HC Wainwright reaffirmed a buy rating and set a $35.00 price objective on shares of Atyr PHARMA in a research report on Thursday, August 15th. Royal Bank of Canada reaffirmed an outperform rating and set a $16.00 price objective on shares of Atyr PHARMA in a report on Wednesday, August 14th.

Atyr PHARMA Price Performance

ATYR stock opened at $1.88 on Thursday. The firm has a 50-day moving average of $1.87. The firm has a market cap of $129.74 million, a price-to-earnings ratio of -2.09 and a beta of 1.22. Atyr PHARMA has a 1 year low of $1.08 and a 1 year high of $2.50. The company has a quick ratio of 7.63, a current ratio of 7.63 and a debt-to-equity ratio of 0.01.

Atyr PHARMA (NASDAQ:ATYR) last posted its earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. On average, analysts expect that Atyr PHARMA will post -0.94 EPS for the current year.

Insider Transactions at Atyr PHARMA

In other news, Director Paul Schimmel acquired 52,300 shares of the business’s stock in a transaction dated Wednesday, July 24th. The stock was acquired at an average price of $1.93 per share, with a total value of $100,939.00. Following the completion of the transaction, the director now directly owns 413,023 shares in the company, valued at approximately $797,134.39. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 3.70% of the company’s stock.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.